Trinity Biotech Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Trinity Biotech wird ein Gewinn- und Umsatzwachstum von 33.2% bzw. 11.8% pro Jahr prognostiziert, während der Gewinn pro Aktie um 55.6% pro Jahr wachsen soll.

Wichtige Informationen

33.2%

Wachstumsrate der Gewinne

55.6%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	17.1%
Wachstumsrate der Einnahmen	11.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	15 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Investors Give Trinity Biotech plc (NASDAQ:TRIB) Shares A 38% Hiding

Sep 25

A Piece Of The Puzzle Missing From Trinity Biotech plc's (NASDAQ:TRIB) 35% Share Price Climb

Aug 07

The Market Lifts Trinity Biotech plc (NASDAQ:TRIB) Shares 34% But It Can Do More

Jun 11

Investors Don't See Light At End Of Trinity Biotech plc's (NASDAQ:TRIB) Tunnel And Push Stock Down 27%

Mar 02

Trinity Biotech plc's (NASDAQ:TRIB) Shares Bounce 31% But Its Business Still Trails The Industry

Dec 18

This Broker Just Slashed Their Trinity Biotech plc (NASDAQ:TRIB) Earnings Forecasts

Apr 23

Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?

Mar 01

Trinity Biotech appoints former GE executive Aris Kekedjian as CEO

Oct 03

At US$1.22, Is Trinity Biotech plc (NASDAQ:TRIB) Worth Looking At Closely?

Sep 01

Trinity Biotech GAAP EPADS of -50c, revenue of $18.78M misses by $1.22M

Jun 30

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:TRIB - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	78	-8	3	6	1
12/31/2025	69	-15	-11	-8	1
12/31/2024	62	-20	-10	-9	1
9/30/2024	59	-20	-16	-7	N/A
6/30/2024	59	-22	-14	-8	N/A
3/31/2024	57	-34	-15	-12	N/A
12/31/2023	57	-37	-14	-12	N/A
9/30/2023	71	-39	-13	-10	N/A
6/30/2023	54	-46	-8	-5	N/A
3/31/2023	74	-34	-7	-2	N/A
12/31/2022	63	-44	-7	-1	N/A
9/30/2022	76	-32	-6	2	N/A
6/30/2022	79	-22	-5	3	N/A
3/31/2022	86	-13	-2	6	N/A
12/31/2021	81	-2	5	13	N/A
9/30/2021	106	-8	11	20	N/A
6/30/2021	116	-2	18	27	N/A
3/31/2021	106	-2	19	29	N/A
12/31/2020	102	-6	14	24	N/A
9/30/2020	91	-20	-1	7	N/A
6/30/2020	83	-27	-6	5	N/A
3/31/2020	90	-31	-2	10	N/A
12/31/2019	90	-29	-6	5	N/A
9/30/2019	94	-30	-4	11	N/A
6/30/2019	93	-29	-7	9	N/A
3/31/2019	95	-23	-7	9	N/A
12/31/2018	97	-23	-10	7	N/A
9/30/2018	97	-39	-10	7	N/A
6/30/2018	99	-40	N/A	8	N/A
3/31/2018	99	-40	N/A	10	N/A
12/31/2017	99	-39	N/A	9	N/A
9/30/2017	98	-36	N/A	8	N/A
6/30/2017	99	-37	N/A	10	N/A
3/31/2017	100	-36	N/A	8	N/A
12/31/2016	100	-39	N/A	10	N/A
9/30/2016	101	3	N/A	17	N/A
6/30/2016	101	16	N/A	14	N/A
3/31/2016	98	16	N/A	13	N/A
12/31/2015	100	22	N/A	13	N/A
9/30/2015	101	23	N/A	15	N/A
6/30/2015	103	15	N/A	17	N/A
3/31/2015	105	17	N/A	16	N/A
12/31/2014	105	15	N/A	16	N/A
9/30/2014	103	18	N/A	8	N/A
6/30/2014	100	10	N/A	6	N/A
3/31/2014	95	10	N/A	8	N/A
12/31/2013	91	10	N/A	9	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: TRIB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: TRIB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: TRIB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: TRIBDie Einnahmen des Unternehmens (11.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: TRIBDie Einnahmen des Unternehmens (11.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von TRIB in 3 Jahren voraussichtlich hoch sein wird

Trinity Biotech Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Trinity Biotech plc Provides Preliminary Revenue Guidance for the Second Quarter of 2024

Trinity Biotech plc Revises Revenue Guidance for the Fourth Quarter of 2024

Trinity Biotech plc Provides Revenue Guidance for the Fourth Quarter of 2023

Consensus EPS estimates fall by 47%

Trinity Biotech plc Provides Revenue Guidance for the Third Quarter of 2023

Consensus revenue estimates fall by 17%

Recent updates

New major risk - Financial position

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Trinity Biotech plc to Report Q3, 2024 Results on Nov 15, 2024

Trinity Biotech Regains Compliance with Nasdaq Listing Requirements

Trinity Biotech plc (NasdaqGS:TRIB) acquired EpiCapture Limited for $3.6 million.

Trinity Biotech plc Announces Positive Pre-Pivotal Trial Results for Its Next-Generation Continuous Glucose Monitor Technology

Second quarter 2024 earnings: EPS misses analyst expectations

Investors Give Trinity Biotech plc (NASDAQ:TRIB) Shares A 38% Hiding

Trinity Biotech plc (NasdaqGS:TRIB) acquired Metabolomic Diagnostics Ltd. for an enterprise value of $1.3 million.

Trinity Biotech plc to Initiate CGM Market Study in India in Furtherance of Intended Collaboration with Bayer

Trinity Biotech plc Provides Update on the Continued Development of its Glucose Biosensor Technology

Trinity Biotech plc, Annual General Meeting, Sep 30, 2024

Trinity Biotech plc Appoints Global Life Sciences Leader Adrian Donohue as Chief Commercial Officer

Trinity Biotech Appoints David Ouston as Biosensor Marketing Director

Second quarter 2024 earnings: Revenues in line with analyst expectations

Trinity Biotech plc to Report Q2, 2024 Results on Aug 14, 2024

A Piece Of The Puzzle Missing From Trinity Biotech plc's (NASDAQ:TRIB) 35% Share Price Climb

Trinity Biotech Obtains an Extension to Demonstrate Compliance with Nasdaq Listing Requirements

Trinity Biotech plc Provides Preliminary Revenue Guidance for the Second Quarter of 2024

Trinity Biotech plc has filed a Follow-on Equity Offering in the amount of $5.5 million.

Trinity Biotech plc has filed a Follow-on Equity Offering in the amount of $5.5 million.

Trinity Biotech plc Announces Chief Financial Officer Changes

Trinity Biotech plc to Begin European Pre-Pivotal Trial to Optimize Its Cgm Sensor

New minor risk - Share price stability

The Market Lifts Trinity Biotech plc (NASDAQ:TRIB) Shares 34% But It Can Do More

Trinity Biotech plc Launches Its Continuous Glucose Monitoring Microsite to Showcase Its Innovative & Differentiated Technology

Trinity Biotech plc Receives A Staff Determination Letter Regarding MVPHS Requirement by May 20, 2024

Trinity Biotech plc to Report Q1, 2024 Results on May 23, 2024

Trinity Biotech plc Revises Revenue Guidance for the Fourth Quarter of 2024

Trinity Biotech Announces the Appointment of Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development

Full year 2023 earnings released: US$4.82 loss per share (vs US$6.46 loss in FY 2022)

Full year 2023 earnings released

Trinity Biotech plc to Report Q4, 2023 Results on Apr 04, 2024

Investors Don't See Light At End Of Trinity Biotech plc's (NASDAQ:TRIB) Tunnel And Push Stock Down 27%

New minor risk - Shareholder dilution

New major risk - Share price stability

Trinity Biotech plc Provides Revenue Guidance for the Fourth Quarter of 2023

Third quarter 2023 earnings released

Trinity Biotech to Begun Shipments of Its New HIV Screening Test, TrinScreen HIV to Kenya

Trinity Biotech plc Announces CEO Changes

Trinity Biotech plc's (NASDAQ:TRIB) Shares Bounce 31% But Its Business Still Trails The Industry

Trinity Biotech plc Appoints Andrew Omidvar as Director

Consensus EPS estimates fall by 47%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Trinity Biotech plc Provides Revenue Guidance for the Third Quarter of 2023

Trinity Biotech plc to Report Q2, 2023 Results on Oct 03, 2023

Now 20% undervalued after recent price drop

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Minimum Bid Price Requirement

A Look At The Fair Value Of Trinity Biotech plc (NASDAQ:TRIB)

Trinity Biotech plc, Annual General Meeting, Sep 29, 2023

Trinity Biotech plc Announces Receives 510(k) Clearance From The U.S. Food and Drug Administration for the Premier Resolution System

Should You Investigate Trinity Biotech plc (NASDAQ:TRIB) At US$0.80?

Consensus revenue estimates fall by 17%

New minor risk - Profitability

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Trinity Biotech plc to Report Q1, 2023 Results on Jul 06, 2023

Insufficient Growth At Trinity Biotech plc (NASDAQ:TRIB) Hampers Share Price

Calculating The Intrinsic Value Of Trinity Biotech plc (NASDAQ:TRIB)

This Broker Just Slashed Their Trinity Biotech plc (NASDAQ:TRIB) Earnings Forecasts

Consensus revenue estimates fall by 11%

Full year 2022 earnings: Revenues in line with analyst expectations

Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 54%

Trinity Biotech plc to Report Q3, 2022 Results on Dec 15, 2022

Second quarter 2022 earnings released: US$0.29 loss per share (vs US$0.037 loss in 2Q 2021)

Less than half of directors are independent

Second quarter 2022 earnings released

Trinity Biotech plc Provides Revenue Guidance for the Third Quarter of 2022

Trinity Biotech plc to Report Q2, 2022 Results on Nov 03, 2022